Ensayos clínicos de Linfoma en Texas
45 estudios sobre Linfoma buscan participantes en Texas.
Ciudades en Texas
Texto oficial del estudio (inglés)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
ReclutandoEstudio observacional
Edades de 0 a 38 · Todos los sexos · Actualizado el 1 oct 2026 · NCT06131801T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- Baylor Scott & White Research Institute, Texas Oncology, Dallas
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06343311A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- The University of Texas - MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07192471A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- MD Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07015242A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center, Dallas
- Baylor College of Medicine, Houston
ReclutandoFase 1/2
Hasta los 25 · Todos los sexos · Actualizado el 25 sept 2026 · NCT04094610Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- University of Texas - MD Anderson Cancer Center, Houston
ReclutandoFase 1
24 Months – 18 Years · Todos los sexos · Actualizado el 25 sept 2026 · NCT06441331A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Texas Oncology - Center South, Austin
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT07221500Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- Sarah Cannon Research Institute at St. David's South Austin, Austin
ReclutandoFase 1
Edades de 18 a 100 · Todos los sexos · Actualizado el 15 sept 2026 · NCT05798897AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, Houston
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06137144CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- Cook Children's Medical Center, Fort Worth
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
ReclutandoFase 1/2
12 Months – 21 Years · Todos los sexos · Actualizado el 11 sept 2026 · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Houston
ReclutandoFase 3
Edades de 18 a 18 · Todos los sexos · Actualizado el 8 sept 2026 · NCT07509151A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Baylor College of Medicine, Houston
- Renovatio Clinical, The Woodlands
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 sept 2026 · NCT06624085TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
- The University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT07082803A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Renovatio Clinical - El Paso, El Paso
- Renovatio Clinical, The Woodlands
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06084936Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Baylor Scott & White Health, Dallas
- MD Anderson, Houston
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT04588922Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT07284433Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Baylor University Medical Center, Dallas
- Texas Transplant Institute, San Antonio
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT05826535Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
- MD Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT06218602Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
- UT MD Anderson, Houston
ReclutandoFase 1
Edades de 12 a 30 · Todos los sexos · Actualizado el 12 ago 2026 · NCT07513129Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 13 a 90 · Todos los sexos · Actualizado el 6 ago 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- St. David's South Austin Medical Center, Austin
- University of Texas Southwestern Medical Center, Fort Worth
- MD Anderson Cancer Center, Houston
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 ago 2026 · NCT07188558A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
- The University of Texas M D Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 jul 2026 · NCT05773040A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
- MD Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 jul 2026 · NCT06563505A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
- MD Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 jul 2026 · NCT05929612A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
- MD Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 jul 2026 · NCT05464719DALY II USA/ MB-CART2019.1 for DLBCL
- UT Southwestern Medical Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- Texas Transplant Institute, San Antonio
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 jul 2026 · NCT04792489A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
- MD Anderson, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 jul 2026 · NCT07465835A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0054), Dallas
ReclutandoFase 1/2
6 Months – 17 Years · Todos los sexos · Actualizado el 6 jul 2026 · NCT02332668A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 jul 2026 · NCT05131022CD4CAR for CD4+ Leukemia and Lymphoma
- The University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 12 en adelante · Todos los sexos · Actualizado el 24 jun 2026 · NCT03829540A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 jun 2026 · NCT05475925CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
ReclutandoFase 1
Edades de 12 a 75 · Todos los sexos · Actualizado el 10 jun 2026 · NCT02917083Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
- M D Anderson Cancer Center, Houston
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 may 2026 · NCT05011045Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
- MD Anderson Cancer Center, Houston
- Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio
Reclutando
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 may 2026 · NCT05676450Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- University of Texas Health Science Center at San Antonio, San Antonio
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 18 may 2026 · NCT01790152CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- The University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 abr 2026 · NCT03328078The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Texas(UT) Southwestern-Children's Medical Center, Dallas
ReclutandoFase 1/2
Edades de 12 a 95 · Todos los sexos · Actualizado el 15 abr 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 mar 2026 · NCT04830137A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- MD Anderson, Houston
ReclutandoFase 2
Edades de 18 a 66 · Todos los sexos · Actualizado el 17 mar 2026 · NCT06859424Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
ReclutandoFase 1
Todas las edades · Todos los sexos · Actualizado el 2 mar 2026 · NCT01555892De ClinicalTrials.gov, datos obtenidos el 2 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.